Patients hospitalized for surgery have higher tobacco abstinence rates after hospital discharge than the general population, particularly if they are undergoing major procedures [ 18- 21].
Preoperative heparin bridging did not reduce the incidence of cardiovascular events, but was associated with an increased risk of major bleeding compared with the 'no-bridging' approach, especially in patients who underwent major procedures.
Intravenous insulin is optimal in the immediate perioperative period for type 1 diabetes, as well as for many type 2 diabetic patients undergoing major procedures and should typically be continued until a patient resumes eating (66, 67).
However, patients at cardiovascular risk undergoing major procedures may benefit from heparin bridging because their outcome in terms of cardiovascular risk is increased and because, in this particular setting, heparin bridging is not an independent factor for bleeding risk.
If patients undergoing major procedures with long lasting anesthesia became hypothermic more often, they were probably not warmed actively as we could suspect from the active warming rate and rate of temperature monitoring of this set of patients.
However, a selection bias resulted from a more frequent use of bridging therapy in severe procedure (most physicians anticipated the increased cardiovascular risk in patients undergoing major procedure).
They concluded that a continuation or short interruption of NOACs is safe for most invasive procedures and that patients with cardiovascular risks undergoing major procedure may benefit from bridging therapy, with as a consequence a higher bleeding risk.
One Florida federal district court has already (and wrongly) ruled that if states may outlaw abortion at some point during pregnancy and force a woman to carry an unwanted pregnancy to term, then surely the state can also force a woman to undergo major medical procedures to deliver the child she "affirmatively desires to have".
Establishing the diagnosis of PC remains a significant clinical problem that delays initiation of therapy, impacts enrollment in clinical trials, and mandates that patients undergo major surgical procedures in the absence of definitive findings.
The stomach is the most common primary site for GIST (~60%), and a proportion of these patients will therefore undergo major gastrectomy procedures prior to systemic imatinib therapy for metastasis [ 25].
